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SUMMERY 
Chronic Obstructive Pulmonary Disease (COPD) is a 
preventable and treatable disease characterised by airflow limitation 
that is not fully reversible with some significant extrapulmonary effects 
that may contribute to the severity in individual patients. Progressive 
decline in airflow is associated with an abnormal inflammatory 
response of the lung to noxious particles or gases (1).  
 Limitation in the exercise capacity is a major characteristic of 
COPD, particularly in moderate-severe disease. This may be 
expressed as dyspnoea occurring during an effort of different intensity, 
and as reduction in the possibility to perform a normal or almost 
normal active life. In more severe patients, exercise limitation is so 
relevant to avoid the patient to leave home and also limiting them in 
the normal home daily activity. Limitation in exercise capacity in COPD 
patients has been demonstrated to be related to different 
mechanisms, which may be differently represented in the same 
patient. These mechanisms are: a) abnormal mechanical properties of 
the respiratory system, leading to ventilatory limitation; b) abnormal 
cardiovascular response to the exercise (cardiac limitation); c) 
reduction in the peripheral muscle strength and endurance, leading to 
muscular limitation. 
Cardiopulmonary exercise testing (CPET) is considered the gold 
standard for exercise intolerance evaluation. During the test, patients 
are subjected to symptom limited incremental exercise, breath-by-
breath monitoring of cardiopulmonary variables (e.g. pulmonary O2 
uptake, pulmonary CO2 output, minute ventilation (Ve ), heart rate 
(HR), assessment of perceptual responses (e.g. dyspnea, leg 
discomfort) and measurements such as exercise-related arterial 
oxygen desaturation, dynamic hyperinflation and limb-muscle strength. 
Other methods for assessing exercise limitation in COPD are: 
endurance time , incremental shuttle walking test (ISWT), endurance 
shuttle walking test (ESWT).To quantify the physical activity in daily 
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life through motion sensors like Armband SenseWear becomes 
important in the valuation of COPD patients. 
Several studies have attempted to correlate the tolerance effort of 
COPD patients with various physiological parameters, clinical, 
metabolic and inflammatory. However, few studies have attempted to 
simultaneously consider many different factors that can contribute to 
determine the limitation exercise in these patients. This is important to 
determine which of several pathophysiological, biological and 
metabolic mechanisms are primarily responsible for limiting the effort 
in individual patients with COPD. 
The aim of the present study was to assess in a large group of 
patients with COPD of different severity, the relative role of the 
different components of the disease which may have influence on the 
response to the exercise. 
In this attempt, we chose the response to the CPET as the more 
accurate method for evaluating the pulmonary, cardiovascular and 
metabolic responses to the exercise, and we tried to correlated the 
response to CPET with several baseline findings. We included a large, 
although not exhaustive, number of measurements, including: a) 
clinical findings (rate of dyspnoea, exacerbation rate, comorbidities); b) 
pulmonary function measurements; c) respiratory muscle strength 
measurements; d) metabolic findings (BMI, FFM, blood haemoglobin); 
e) markers of airway and systemic inflammation (derived from induced 
sputum, exhaled breath or peripheral blood) or cardiac involvement 
(pro-BNP). We tried also, in a multivariate analysis performed of all 
examined patients and in subgroups of patients according to the main 
factor limiting exercise, to assess the main determinants, among those 
already mentioned, which may have influence on the exercise 
limitation.  
 
Study design 
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The study is a cross-sectional study and took place in three visits, 
along a study period of 2 weeks. 
We studied fifty-one outpatients with stable COPD between July 
2008 and May 2010, recruited among those attending to the clinics of 
our Respiratory Pathophysiology Unit of the Cardio-Thoracic and 
Vascular Department of the University of Pisa. 
Three patients didn‟t perform the cardiopulmonary exercise test 
(CPET),  two patients dropped out before performing the CPET, and 
one patient was defined at the examination as affected by a relevant 
asthma-like component of the disease. Forty-five patients were 
therefore included in the analysis.  
The patients performed: pulmonary function test, arterial blood 
analysis, maximal inspiratory (MIP) and expiratory (MEP) pressures, 
incremental shuttle walking test, cardiopulmonary exercise test 
(CPET). Physical activity was measured over at least 7 consecutive 
days, using a multisensory Armband. Metabolic status was evaluated:  
body mass index (BMI), Fat Free Mass (FFM) and Fat Free Mass 
Index (FFMI). The Saint George‟s Respiratory Questionnaire (SGRQ) 
was used for the assessment of the health-related quality of life. 
Charlson index and CIRS index (Cumulative illness rating scale ) were 
used as valid and reliable methods to measure comorbidity. In a 
sample of venous peripheral blood, the following biomarkers were 
measured: C-reactive protein (CRP), total and differential inflammatory 
cells, haemoglobin and N-terminal pro–B-type natriuretic peptide (NT-
pro-BNP) concentration, as a systemic biomarker of heart failure. 
Sputum was induced and measured: macrophage, lymphocyte, 
neutrophil, eosinophil percentages were expressed as percent of total 
inflammatory cells, excluding squamous cells. In the sputum were 
measured supernatant, TNF-alfa,  IL-8 and neutrophilic elastase (NE). 
Exhaled nitric oxide (NO) were measured and exhaled breath 
condensate (EBC) was collected. 
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Statistical analysis was performed on the data obtained in the 45 
patients who performed all measurements. All statistical analyses 
were performed using a SPSS 16.0 statistical package.  
 
Results 
We considered as dependent variable VO2peak/kg, which may 
be considered the best way for expressing exercise limitation during 
CPET, and as independent variable all these findings which may 
potentially have some influence in determining the amount of the 
exercise limitation. In an univariate single regression analysis, 
V02peak/Kg was significantly correlated with MRC score, FEV1%  
FVC %, SVC % FEV1/SVC % IC % RV/TLC %, DLCO %. 
 As regards the correlation with biomarkers measured in the 
blood, sputum and exhaled condensate  we can see that there was no 
significant correlations of VO2peak/kg for many biomarkers, except for 
some indices of systemic inflammation blood neutrophil %, serum IL-8, 
blood microparticles,  blood haemoglobin and serum N-Pro-BNP. 
In a stepwise regression analysis we observed that the only 
variable that explains the model was blood haemoglobin and total 
variance explained by this model was 31.5%. 
Excluding haemoglobin aspecific parameters,  the variable that 
explains the model is MRC score, with total variance explain of 20.5 
%. 
If we consider one independent variable for each clinical , 
functional and biological field, DLCO % is the variable that explains 
the model and total the variance explain was 19.6%. 
Other correlations for VO2peak/kg with: ISWT, as expected, 
steps/day and SGRQ.  
Divided the patients in flow limitation (FL) and no flow 
limitation(NFL), according Hyatt technique, only in the FL group the 
VO2peak/Kg correlated in univariate analysis with a several clinical 
functional and biological indices (MRC, FEV1%, IC%, DLCO%; 
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steps/day, SGRQ tot %). In stepwise regression analysis MRC and 
IC% were the parameters that enter in the analysis, with cumulative 
R2= 0.454.  
Considering the patients that had interrupted the CPET for ventilator 
limitation (30 patients out of 45) in univariate analysis VO2peak/Kg 
correlated with MRC, FEV1%, IC%, DLCO%, MIP, serum pro-BNP, 
TEE, ISWT, SGRQ tot %. In stepwise regression analysis were 
excluded ISWT and parameters of Armband; only MRC entered in the 
model (p= 0.021, R= 0.589) and explained the  34.7% of variance of 
exercise tolerance.  
In the patients that interrupted the CPET for muscular limitation 
(15 patients), the exercise tolerance not correlated with functional 
parameters but several indices: age, blood neutrophils %, blood 
eosinophils %, sputum neutrophils %, ISWT. This patients had less 
compromise in FEV1% and higher MRC score than the 30 patients 
that stopped CPET for ventilator limitation. 
 
Conclusion 
In the present cross sectional study, we tried to examine the 
determinants of the exercise limitation which is a characteristic of the 
patients with moderate-severe COPD. We included a large, although 
not exhaustive, series of clinical, functional and biological 
measurements, in order to find which variable, among those 
considered, might have the predominant role in determining the 
limitation in exercise capacity. We chose the maximum specific 
oxygen consumption (VO2peak/kg), obtained during a CPET, as a 
good marker of the exercise limitation in our COPD patients. We found 
that several clinical, functional and biological variables were 
significantly correlated with VO2peak/kg. Many of these correlations 
were expected according to the pathophysiology of the disease (like 
MRC, IC, DLCO), but some of them were fairly unexpected (like some 
biomarkers). Furthermore, our study was not able to show significant 
 8 
correlations with other variable which may be considered as possible 
determinants of the exercise capacity (like respiratory muscle strength, 
BMI or FFM). When me included the variables which resulted 
significantly correlated with VO2max/kg in a multivariate step-wise 
regression (according to different models), we found that the man 
determinants were haemoglobin and, in a second position, MRC 
dyspnoea score and diffusing capacity. This was particularly true when 
only subjects with pulmonary mechanical factors which may limit 
exercise (like the presence of flow limitation), or with a respiratory 
limitation to the CPET, were considered. This suggest that the main 
factors limiting the peak oxygen consumption during exercise are 
represented by non-pulmonary mechanisms in all unselected COPD 
patients, and by pulmonary mechanisms in COPD patient with clear 
limitation to the exercise related to the pulmonary disease. 
 
Limitation of the study 
Our study has some limitation. Firstly, we have not directly 
measured the strength of lower limb muscle, which are main 
determinants of the maximum work load sustained during the CPET. 
Secondly, we have no independent measure of the heart 
function (like ejection fraction or other indices derived from 
echocardiography). We know that exercise limitation is strongly related 
to the performance of the cardiovascular system. 
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Abbreviation 
 
VO2peak Oxygen uptake at peak exercise 
VCO2 carbon dioxide output 
WR Wark rate 
RER  respiratory exchange ratio 
Vt tidal volume 
Vd Dead space 
Ve Minute ventilation 
HR Heart rate 
HRR Heart rate reserve 
FEV1 forced expiratory volume in 1 second 
VC vital capacity 
FVC  Forced vital capacity 
IC Inspiratory capacity 
TLC Total lung capacity 
FRC Functional residual capacity 
RV Residual volume 
DH Dynamic Hyperinflation 
EELV end-expiratory lung volume 
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CHAPTER I 
 
INTRODUCTION 
 
Chronic Obstructive Pulmonary Disease (COPD) is a preventable 
and treatable disease characterised by airflow limitation that is not fully 
reversible with some significant extrapulmonary effects that may 
contribute to the severity in individual patients. Progressive decline in 
airflow is associated with an abnormal inflammatory response of the 
lung to noxious particles or gases (1). COPD is a leading cause of 
disability and death worldwide, with variable data of population 
prevalence rates 5% to 13% (2). Prevalence rates are related directly 
to tobacco smoking and indoor air pollution, and are expected to rise 
as smoking rates continue to increase, notably among women and in 
developing countries, as a consequence by 2030, COPD is expected 
to represent the third leading cause of death in middle-income 
countries. In addition, COPD accounts for a significant proportion of 
health care budgets, mainly due to hospitalisations for exacerbations 
(2). 
 COPD is characterised by progressive decline in respiratory 
function and health related quality of life (HRQoL) with substantial risk 
for premature death (3). The pathologic effects of COPD on the 
respiratory system affect the proximal and peripheral airways, lung 
parenchyma, and vasculature (4). Moreover, comorbidities such as 
cardiovascular disease, diabetes mellitus, and depression, as well as 
associated systemic consequences, including weight loss and muscle 
dysfunction, increase the overall burden of disease (5).  The clinical 
course of COPD has been viewed as a progressive decline in lung 
function over time (measured in terms of forced expiratory volume in 
one second (FEV1) (6). However, recent work suggests that disease 
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progression is very heterogeneous, the clinical course and 
presentation depend on contributing phenotypes (7). A majority of 
patients show no statistical significant decline of FEV1 or increase in 
the Body mass index, degree of airflow Obstruction, functional 
Dyspnoea, and Exercise capacity (BODE) index. The multidimensional 
evaluation of COPD should offer insight into response to COPD 
management (8). 
 Limitation in the exercise capacity is a major characteristic of 
COPD, particularly in moderate-severe disease. This may be 
expressed as dyspnoea occurring during an effort of different intensity, 
and as reduction in the possibility to perform a normal or almost 
normal active life. In more severe patients, exercise limitation is so 
relevant to avoid the patient to leave home and also limiting them in 
the normal home daily activity. Limitation in exercise capacity in COPD 
patients has been demonstrated to be related to different 
mechanisms, which may be differently represented in the same 
patient. These mechanisms are: a) abnormal mechanical properties of 
the respiratory system, leading to ventilatory limitation; b) abnormal 
cardiovascular response to the exercise (cardiac limitation); c) 
reduction in the peripheral muscle strength and endurance, leading to 
muscular limitation. 
Expiratory flow limitation (EFL) is the pathophysiologic hallmark 
of COPD and arises because of the dual effects of permanent 
parenchymal destruction (emphysema) and airway dysfunction, which 
in turn reflects the effects of small airway inflammation (mucosal 
edema, airway remodeling/fibrosis, and mucous impaction). In COPD, 
the increased compliance of the lung, as a result of emphysema, leads 
to a resetting of the relaxation volume of the respiratory system to a 
higher level than in health. This has been termed “static” lung 
hyperinflation. In patients with EFL during spontaneous resting 
breathing, end-expiratory lung volume (EELV) is also dynamically 
determined and is maintained at a level above the statically 
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determined relaxation volume of the respiratory system. In flow-limited 
patients, the time-constant for lung emptying (i.e., the product of 
compliance and resistance) is increased in many alveolar units, but 
the expiratory time available (as dictated by the respiratory control 
centers) is often insufficient to allow EELV to decline to its normal 
relaxation volume, thereby resulting in air retention (or trapping) with 
further lung hyperinflation. The rate and magnitude of dynamic lung 
hyperinflation (DH) during exercise is generally measured in the 
laboratory setting by serial inspiratory capacity (IC) measurements. 
The negative effects of acute DH during exercise are now well 
established:  
1) DH leads to increase in the elastic and threshold loads on the 
inspiratory muscles, thus increasing the work and oxygen cost 
of breathing; 
2) DH results in functional inspiratory muscle weakness by 
maximally shortening the muscle fibers in the diaphragm and 
other inspiratory muscles; 
3) DH reduces the ability of tidal volume to expand appropriately 
during exercise, and this leads to early mechanical limitation of 
ventilation; 
4) In some patients, this mechanical constraint on tidal volume 
expansion in the setting of severe pulmonary V/Q abnormalities 
(i.e., high fixed physiological dead space) leads to CO2 
retention and arterial oxygen desaturation during exercise;  
5) DH adversely affects dynamic cardiac function. 
The role of static and dynamic hyperinflation in determining the 
symptoms of COPD patients is demonstrated also by the improvement 
in dyspnoea after bronchodilators and lung volume reduction surgery, 
which correlates with increased IC, a measure of reduced lung 
hyperinflation. (9). 
Tzani et al. (10) have found that dynamic hyperinflation is strictly 
associated to a poor cardiovascular response to exercise in COPD 
 13 
patients with different degree of severity. In 48 COPD patients there 
was a significant and inverse relationship between the peak exercise 
EELV and the change in oxygen pulse achieved on exercise. The 
oxygen pulse does not directly measure the stroke volume, but it may 
be considered as a surrogate marker, when arterial oxygen content 
can be assumed to be normal (11) 
Dynamic hyperinflation may reduce left ventricle stroke volume since 
increases intrathoracic pressures and, consequently, decreases the 
preload by reducing both venous return and the volume of the left 
ventricle. As a consequence, there is a reduced filling of the left 
ventricle and consequently a reduced cardiac output. Moreover,  DP 
(double product)  reserve was inversely related to the dynamic 
hyperinflation during exercise. In addition, heavy hyperinflators had a 
high likelihood to have a DP reserve value ≤ 10,000 mmHg · bpm. 
Lastly, in all patients, DP reserve was inversely related to 
breathlessness perception at peak exercise, suggesting that in COPD 
patients the exertional dyspnoea may be due not only to ventilator 
constrains, but also to a functional cardiovascular impairment. DP 
reserve is used as an estimate of the maximal performance of the left 
ventricle. DP reserve reflects myocardial oxygen uptake during 
exercise, since the three major determinants of myocardial oxygen 
uptake are the tension in the wall of the ventricle, the contractile state 
of the heart and the heart rate.(12). 
A reduced capacity for muscle aerobic metabolism may 
influence exercise tolerance in several ways. Increased lactic acidosis 
for a given exercise work rate, a common finding in COPD increases 
ventilatory needs. This imposes an additional burden on the 
respiratory muscles already facing increased impedance to breathing. 
Premature muscle acidosis, a contributory factor to muscle task failure 
and early exercise termination in healthy subjects, may be an 
important mechanism contributing to exercise intolerance in COPD. 
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This is exacerbated by a tendency to retain CO2 during exercise, 
further increasing acidosis. (13) 
Unexplained weight loss occurs in about 50% of patients with 
severe COPD, but it can also be seen in about 10 to 15% of patients 
with mild to moderate disease. It is mostly due to loss of skeletal 
muscle mass and, whenever it occurs, it highlights poor prognosis. 
Weight loss in COPD is mostly due to skeletal muscle atrophy. 
Furthermore, the remaining muscle mass is often dysfunctional.  This 
combination contributes significantly to reduce the exercise capacity 
(and thus, the health status) of patients with COPD. 
The mechanisms underlying skeletal muscle abnormalities in COPD 
are not precisely defined, but they are probably multiple and 
interdependent. Systemic inflammation is a likely contributor. For 
instance, cytokines, particularly TNF-alpha, activate the transcription 
factor nuclear factor (NF)-KB, up-regulate the inducible form of the 
nitric oxide synthase, and facilitate the degradation of myosin heavy 
chains through the ubiquitin–proteasome complex .They can also 
promote apoptosis in skeletal muscle cells, as recently shown to occur 
in patients with COPD and low body weight. (14) 
 
Methods for the assessment of exercise capacity in COPD 
Cardiopulmonary exercise testing 
Cardiopulmonary exercise testing (CPET) provides a global 
assessment of  the integrative response to exercise involving 
respiratory, cardiovascular, haematopoietic, neuropsychological and 
skeletal muscle systems, which can‟t be adequately studied through 
measurements of individual organ (15). This test is more suitable to 
study the functioning of the several systems involved in exercise, with 
better results than  classical cardiologic protocols with ECG only (16). 
CPET allows evaluation of several parameters involved in 
exercise, both during (real-time) and after the test. They are: 
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 Metabolic parameters: oxygen consumption (VO2), CO2 output 
(VCO2),  respiratory exchange ratio (RER = VCO2/VO2), anaerobic 
threshold (AT); 
 Cardiovascular parameters: maximum workload (Wmax, 
measured in Watt), heart rate (HR) and heart rate reserve (HRR = 
[220-age] – HRpeak), blood pressure (BP), oxigen pulse (O2pulse = 
VO2/HR, which provides information about heart and peripheral 
circulation efficiency during exercise), percutaneous blood saturation 
(SpO2); 
 Respiratory parameters: external ventilaton (VE), tidal volume 
(Vt), breath frequency (Bf) and ventilatory reserve (Br = MCV – 
VEpeak, with MCV as  Maximum Ventilatory Capacity, calculated as 
FEV1 x 40, that in COPD patient is an acceptable assessment of 
Maximum Voluntary Ventilation (I)),   Vd/Vt ratio (a 
ventilation/perfusion mismatch index), inspiratory capacity (IC, to 
evaluate dynamic hyperinflation), end-tidal PaO2 and  PaCO2 (PETO2 
e PETCO2). 
In order to collect these measurements, an adequate equipment 
is needed: a cycle ergometer, a 12-lead ECG, a sphygmomanometer, 
a pulseoxymeter and a pneumotachograph to measure volumes and 
pressure of inspired and expired gases, and a sowftare able to show 
results on a monitor.  Actually, more reliable measurements could be 
possible using more invasive methods, such as arterial catheterism for 
invasive blood pressure assessment, blood gases sampling, oxygen 
saturation and anaerobic threshold: usually non-invasive 
measurements are sufficiently reliable to avoid use of invasive tools.    
The previously mentioned parameters are integrated with the 
real-time evaluation (during CPET), of dyspnea and muscular fatigue 
according to Borg scale. This last evaluation is useful to correlate 
measured parameters with subjective feelings of patients, in order to 
better assess exercise tolerance.  
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The correlation between the several variables recorded during 
the test, according to the method proposed by Wassermann and 
coworkers (16) allows a comprehensive evaluation of individual 
response to exercise. Figure 1 shows a maximal effort of a normal 
individual.  
The mechanisms of the adaptation to the exercise in a normal 
subjects involves different steps and physiologic effects. Once 
contraction of locomotor muscles begins, there deliver both central 
and peripheral mechanisms governing the appropriate regulation of 
cardiopulmonary responses. VO2 rises fairly linearly with work rate 
through-out progressive exercise because of an increase in cardiac 
output (HR x SV) and increased oxygen extraction at the tissues. Early 
exercise is associated with a combined increase in stroke volume (not 
shown) and heart rate, whereas late in exercise the rise in cardiac 
output is mostly dependent on increases in heart rate. Oxygen pulse 
also rises linearly early in exercise, but tends to plateau later in 
exercise as both SV and the C(a–v)O2 begin to plateau. VO2 is 
relatively insensitive to small changes in VE (e.g., hyperventilation) as 
long as the VE is adequate to maintain PaO2. Ventilation rises early in 
exercise as a result of an increase in tidal volume (Vt) and breath 
frequency (Bf) of breathing. As exercise progresses, Vt tends to level 
off at about 50% of the VC (likely in part to limit the elastic load 
associated with high and low lung volumes) and subsequent increases 
in VE are due to increases in Bf (increasing three- to fourfold from 
resting levels). 
Ventilation increases linearly withVO2 and VCO2 until the 
approximate time when lactate begins to increase in the arterial blood. 
At this point, VE and VCO2 begin to increase out of proportion toVO2. 
The rise in VE is initially sufficient to compensate for the metabolic 
acidosis. Buffering of the lactic acidosis yields the increase in VCO2 
with respect to VO2. Thus the ventilatory equivalents for VCO2 fall 
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with light exercise and stay constant with moderate exercise while the 
ventilatory equivalents for VO2 begin to rise. 
The dead space ventilation (in absolute terms) increases with 
exercise; however, the dead space–tidal volume ratio (Vd/Vt) falls. 
There is a tendency for Vd/Vt to increase slightly near peak exercise 
as increases and in some cases Vt falls. (15) 
With respect to the subject show in figure 1 (A), a COPD patient 
shows a different pattern in many variables: 
 VO2peak: it is usually reduced, greater than predicted maximum 
value, as the disease progresses (even if the slope of VO2/WR ratio is 
usually normal), because of reduced exercise tolerance (ventilatory 
limitation, skeletal muscle or heart impairment);  
 Anaerobic threshold (AT): it can be normal or, more usual, 
reduced (that is, AT reached at a VO2 value lower than predicted); in 
more advanced stages of disease, the subject may be not able to 
reach AT; 
 Maximum heart rate (HRpeak) and heart rate reserve (HRR): 
HRpeak is usually reduced (and therefore HRR is higher), indicating a 
sub-maximal  cardiovascular effort, because of ventilatory limitation to 
exercise; with the disease progression, HRpeak becomes 
progressively lower, and HRR higher; this pattern may be different in 
case of coexisting heart disease (for example heart failure); 
 Oxigen pulse (O2pulse): it is usually reduced in proportion to 
VO2peak reduction; this may be due to several causes: ventilatory 
limitation, deconditioning, hypoxemia, arterial disease; 
 Ventilation (VE), breath frequency (Bf) and breathing reserve 
(Br): ventilation is increased to the same load compared with healthy 
individuals (because of higher Bf), with a reduced Br, that tends to 
zero, showing the ventilatory limitation to exercise.  
 Tidal volume (Vt), end-expiratory lung volume (EELV) and 
inspiratory capacity (IC): because of the dynamic hyperinflation, Vt is 
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reduced to same load compared to healthy individuals, while EELV is 
higher and IC is lower, because patient‟s respiratory system is working 
on higher volumes, to ensure adequate flows; 
 Vd/Vt ratio: usually is higher, and it‟s an index of 
ventilation/perfusion mismatch (also showed by high VE/VCO2 ratio), 
that contributes to the increase ventilatory request and, therefore, to 
impaired exercise capacity; 
 Oxygen arterial partial pressure (PaO2) and alveolar-arterial 
difference in PaO2 (P[A-a]O2): while in healthy individuals PaO2 is 
almost constant during the test, and P(A-a)O2 slightly increases 
because of increased alveolar ventilation, in COPD patients usually a 
reduction in PaO2 is observed, with out-of-proportion increase in P(A-
a)O2, both for ventilation/perfusion mismatch and for diffusion 
impairment (especially in advanced stage of disease), both these 
conditions being aggravated during the exercise which reduces the 
transit time of the blood in the alveolar capillaries. Figure 2 shows a 
CPET performed by a patient affected by COPD 
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Figure 1. Progressive changes in several indices of ventilary, 
cardiovascular and metabolic response to the exercise, measured as 
work rate (in watts) or in VO2max (in L/min), in a normal subject (16) 
 
 
Figure 1. CPET in normal individuals 
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Figure 2. Progressive changes in several indices of ventilatory, 
cardiovascular and metabolic response to the exercise, measured as 
work rate (in watts) or in VO2max (in L/min), in a patient with COPD 
(16) 
 
 
 
 
 
 
 
 
 
Figure 2. CPET in COPD patient  
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Other methods for assessing exercise limitation in COPD 
 
Endurance time 
Endurance time during high-intensity exercise is increasingly 
used to assess exercise tolerance before and after a therapeutic 
intervention. Work-rates used in recent clinical studies were 75–80% 
of VO2peak or peak work-rate measured during symptom-limited 
incremental CPET. In addition to the limit of tolerance, comparisons of 
symptom intensity (e.g. dyspnoea, leg effort) or physiological variables 
of interest (e.g. IC, VE, VO2, V9E/VCO2, fC) at a standardised time 
(isotime) have proven very useful in identifying the underlying 
physiological mechanisms responsible for increases in exercise 
tolerance induced by a particular intervention. Recent data from the 
literature support the notion that in COPD patients, endurance tests 
are more sensitive than other exercise protocols in detecting exercise-
related physiological changes induced by interventions, and are thus 
very useful in clinical practice (17). 
High-intensity constant-load protocols (e.g. 75–80% peak work-
rate) have been used to demonstrate the positive effects of 
interventions such as bronchodilator therapy; oxygen and heliox 
administration during exercise; bronchoscopic lung volume reduction 
and rehabilitation. By using this approach, it is possible to demonstrate 
a significant improvement in endurance time, mostly due to a reduction 
in lung dynamic hyperinflation and dyspnoea at isotime. The 
„„highintensity‟‟exercise endurance protocol should therefore now be 
considered the test of choice in evaluating the effects of therapeutic 
interventions in COPD. (18) 
 
Walking tests 
The walk tests are broadly divided in two categories: 
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1) Self-paced test, in which the patients self-selects the speed  of 
walking to meet the aims of the test, as six minutes walking test 
(6MWT); 
2) Externally paced test, in which the speed of walking is imposed 
by pre-recorded signals as incremental shuttle walking test 
(ISWT) and endurance shuttle walking test (ESWT) 
The 6-MWT has been widely used in many large trials exploring 
the benefits of rehabilitation, pharmaceutical intervention, oxygen 
supplementation and surgery in cardiorespiratory disease.  The test is 
used to investigate the effects of interventions on patients‟ walking 
endurance capacity. Measurements of Sp,O2 and Cf may be included 
to detect physiological improvements associated with improvements in 
exercise tolerance. Toosters et al. proposed that a meaningful 
difference in performance for patients with COPD was 52 m in a study 
of the short- and longer-term benefits of pulmonary rehabilitation 
delivered over a 6-month period. (19). Results from similar 
rehabilitation studies confirm the magnitude of change. 
The 6MWT is a practical simple test that requires a 100-ft hallway 
but no exercise equipment or advanced training for technicians. It 
evaluates the global and integrated responses of all the systems 
involved during exercise, including the pulmonary and cardiovascular 
systems, systemic circulation, peripheral circulation, blood, 
neuromuscular units, and muscle metabolism. It does not provide 
specific information on the function of each of the different organs and 
systems involved in exercise or the mechanism of exercise limitation, 
as is possible with maximal cardiopulmonary exercise testing. (20). 
The 6-MWT has been shown to be a sub maximal high-intensity 
constant-load test (21) and most activities of daily living are performed 
at submaximal levels of exertion ,so the 6MWD may better reflect the 
functional exercise level for daily physical activities. 
The incremental SWT (ISWT) has not been extensively 
incorporated into pharmacological studies, but has been cited in a 
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number of significant rehabilitation studies, although it relationships 
with spirometric data and health-related quality of life not been widely 
reported. There is a correlation between ISWT performance and 
grades of MRC dyspnoea scale. Bestall et al. (22) reported significant 
difference in performance of the ISWT for each MRC grade. The ISWT 
has also been usefully employed in elderly patients with COPD, the 
mean distance completed in this group was 177 m (23). The ISWT 
evoked a lower VCO2 peak  and blood lactate concentration than 
incremental test, suggesting a reduced contribution from nonaerobic to 
energy production, influenced by the different muscle groups 
employed for the two activities. (24). The ISWT appears to provoke a 
miximal response that may be more appropriate for the evaluation of 
functional capacity. A large rehabilitation study reported mean 
changes of 75.9 m (25).  
The Endurance shuttle walking test (ESWT) is derived from 
ISWT, but it is designed to assess endurance capacity. The speed of 
walking is calculated from the distance completed on an initial ISWT. A 
speed approximating to a percentage of peak performance is 
identified, this is commonly 60-85%. The ESWT is more sensitive to 
change after a course of rehabilitation than the ISWT. Revill et al. 
reported a mean increase in ESWT of 160%  compared to the ISWT 
change of 32%. (26) 
 
Monitoring of physical activity 
There are the two kinds of instruments more commonly used to 
quantify the amount of physical activity performed by COPD patients in 
daily life: subjective methods (questionnaires, diaries) and motion 
sensors (electronic or mechanical methods). 
Quantifying physical activity in daily life through questionnaires 
and diaries has the advantage of being inexpensive and easy to apply. 
These techniques are known to depend on the following factors, which 
may induce inaccuracy or bias in the assessments: 
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1) Accurate perception and recall of information by the subject. 
2)  The questionnaire‟s design. Questionnaires with an interval 
response option (e.g. how many days in a week walking is 
performed) showed higher self-reported amounts of physical 
activity when compared to „„open‟‟ questions. 
3) Individual characteristics such as age, cultural factors, work 
status and cognitive capacity. 
4) The table of energy costs used in case the outcomes of 
questionnaires and diaries are converted into an estimate of 
energy expenditure. Energy cost of different activities varies 
substantially among subjects as it depends on factors such as 
body mass and movement efficiency and not all activities 
carried out in daily life have a known energy cost. 
Motion sensors are instruments used to detect body movement, 
which can be used to objectively quantify physical activity in daily life 
over a period of time. These instruments basically include pedometers 
(measurement of steps) and accelerometers (detection of body 
acceleration). Pedometers are small, simple and inexpensive 
instruments. They are usually worn on the waist and contain a 
horizontal, spring-suspended lever arm that deflects with vertical 
acceleration of the hips during walking (the up-and-down motion 
during ambulation). Since pedometers were designed to detect vertical 
movement, they most logically assess number of steps. Any 
movement in the vertical plane, like getting up from a chair, can be 
eventually detected and will also result in a motion count. The use of 
pedometers has been promoted to stimulate and monitor walking in 
the general population, since it is suggested that 10,000 steps per day 
could be effective for prevention of disease and promotion of a 
healthier lifestyle. Disadvantages of these devices include the 
tendency to underestimate very slow walking and the fact that some 
devices require that the subjects periodically write down the output of 
the assessment in case of multiple days of measurement. 
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Accelerometers are technologically more advanced devices that allow 
the quantity and intensity of movements to be determined. These 
devices are able to store data continuously over long periods of time, 
and the monitors must be worn without interference in the subject‟s 
normal pattern of activities. Accelerometers are basically of two kinds: 
uniaxial and multiaxial. Uniaxial sensors detect motion in only one 
body dimension (or plane), and may be inaccurate for activities with 
static trunk movement, such as cycling and rowing. The information 
provided is comparable to a pedometer. Multiaxial devices are able to 
detect motion in more than one plane of movement. Some multiaxial 
devices are able to detect a variety of body positions and physical 
activities, and are often denominated activity monitors. A major 
advantage of multiaxial accelerometers is that these devices are able 
to provide more detailed information than the previously mentioned 
types of motion sensors. Disadvantages of accelerometers include the 
higher costs compared with pedometers and the need for technical 
expertise and additional hardware/software to analyse the data. In 
addition, these devices may be sensitive to vibrational artefacts, for 
example, recording vibration related to being in a vehicle. 
Armband SenseWear (BodyMedia Inc., Pittsburgh, PA, USA) is 
a relatively new device worn on the upper arm. The device contains a 
biaxial accelerometer (longitudinal and transverse), although it also 
collects a variety of data through other multiple sensors (e.g. heat and 
temperature). It has been introduced as a fitness accessory or an 
energy consumption monitor since it provides an estimation of energy 
expenditure based on specific algorithms. It also provides the duration 
of activities performed by the individual above a determined level of 
intensity (e.g. 2.5 metabolic equivalents), as well as the number of 
steps. The device was validated against indirect calorimetry in young 
adults and provided valid estimates of energy expenditure, although it 
was necessary to apply exercise-specific algorithms to enhance the 
accuracy of the estimation. (27) 
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Determinants of the exercise capacity in COPD patients 
 
Several studies have tried to correlate the exercise capacity in 
COPD patients, as assessed by different tools, to several clinical and 
functional characteristics. 
In the literature there are already studies that analyze the 
influence of some parameters on exercise tolerance and quality of life 
of patients with COPD. 
In one such study, Trazaska-Sobczak et al. have verified the 
accuracy a new index, the area under the curve maximal expiratory 
flow-volume, in predicting exercise tolerance in patients with COPD 
and assessment of disease severity. (28). Other studies have focused 
on highlighting the role of the inspiratory capacity in exercise tolerance 
in patients with and without flow-limitation at rest, and concluded that 
the inspiratory capacity (IC) is the best element predictor of exercise 
tolerance in flow-limited patients reflecting the presence of dynamic 
hyperinflation, while the FEV1/FVC ratio is the best predictor in flow-
limited patients (29) 
Salepçi et al. have studied the correlation between malnutrition 
and exercise tolerance and concluded that a low body mass index and 
weakness of the respiratory muscles are closely correlated with the 
degree of dyspnea. (30) 
Other studies have been conducted to determine whether the 
diffusion capacity for CO (DLCO) could be a predictor of the need to 
supplemental oxygen during rest and exercise, and then the ability of 
perform physical activity, showing that patients with reduced DLCO 
(especially <20% predicted) have a reduction in PaO2 at rest and 
require oxygen for mild physical activity (31)  
Lee et al. have shown that the changes of hs-RCP (high 
sensitivity C-reactive protein) in the blood are proportionally and 
inversely correlated to the exercise tolerance, so that patients treated 
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with pravastatin, who demonstrated a significant reduction in hs-PCR, 
showed a greater ability to perform physical activity.(32). Spruit et al 
evaluated 16 patients with clinically stable COPD the change of 
circulating levels of C reactive protein, interleukin 6, interleukin 8 and 
insulin-like growth factor, before at the end and 2 and 30 minutes after 
a symptom-limited peak cycling test and before, at the end and 2 and 
30 minutes after a symptom-limited constant-work-rate cycling test at 
70% of the peak load. Non-significant changes in the circulating 
markers of inflammation and anabolism were found. (33) 
Gosselik at al. evaluated determinants of exercise capacity 6-
min walking distance and maximal oxygen consumption (VO2max) in 
41 consecutive COPO patients. In single regression analysis, 
significant correlations were found for V02max and DLCO , FEV1 , 
quadriceps force, hand grip force, and body weight, while walking 
distance was significantly correlated with quadriceps force, hand grip 
force and DLCO. In stepwise regression analysis the variables 
significantly contributing to 6 MWT were quadriceps force and max 
inspiratory pressure, while for V02max, variables significantly 
contributing were DLCO. Quadriceps force and FEV1 and Total 
variance explained by this model was 58%. (34) 
In recent studies other parameters of exercise tolerance as the 
measure of physical activity daily have been evaluated. Wats et al. 
investigated the association of extrapulmonary effects of the disease 
and its comorbidities with reduced physical activity in 170 COPD 
patients. In a multivariate linear regression analysis using either steps 
per day or physical activity level as a dependent variable, N-terminal 
pro–B-type natriuretic peptide levels, echocardiographically measured 
left ventricular diastolic function, and systemic inflammation expressed 
as fibrinogen were associated with reduced physical activity.(35) 
In conclusion, numerous studies have attempted to correlate 
the tolerance effort of COPD patients with various physiological 
parameters, clinical, metabolic and inflammatory. However, few 
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studies have attempted to simultaneously consider many different 
factors that can contribute to determine the limitation exercise in these 
patients. This is important to determine which of several 
pathophysiological, biological and metabolic mechanisms are primarily 
responsible for limiting the effort in individual patients with COPD. 
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CHAPTER II 
AIM OF THE STUDY 
 
The aim of the present study was to assess in a large group of 
patients with COPD of different severity, the relative role of the 
different components of the disease which may have influence on the 
response to the exercise. 
In this attempt, we chose the response to the CPET as the more 
accurate method for evaluating the pulmonary, cardiovascular and 
metabolic responses to the exercise, and we tried to correlated the 
response to CPET with several baseline findings. We included a large, 
although not exhaustive, number of measurements, including: a) 
clinical findings (rate of dyspnoea, exacerbation rate, comorbidities); b) 
pulmonary function measurements; c) respiratory muscle strength 
measurements; d) metabolic findings (BMI, FFM, blood haemoglobin); 
e) markers of airway and systemic inflammation (derived from induced 
sputum, exhaled breath or peripheral blood) or cardiac involvement 
(pro-BNP). We tried also, in a multivariate analysis performed of all 
examined patients and in subgroups of patients according to the main 
factor limiting exercise, to assess the main determinants, among those 
already mentioned, which may have influence on the exercise 
limitation.  
Furthermore, we compared also the results of the CPET with 
other measurements of exercise tolerance, like the response to the 
ISWT, the assessment of daily physical activity by Sensorwear 
Armband, and S. George Respiratory Questionnaire. 
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CHAPTER III 
 
PATIENTS AND METHODS 
 
Study population 
 
We studied fifty-one outpatients with stable COPD between July 
2008 and May 2010, recruited among those attending to the clinics of 
our Respiratory Pathophysiology Unit of the Cardio-Thoracic and 
Vascular Department of the University of Pisa. 
Three patients didn‟t perform the cardiopulmonary exercise test 
(CPET),  two patients dropped out before performing the CPET, and 
one patient was defined at the examination as affected by a relevant 
asthma-like component of the disease. Forty-five patients were 
therefore included in the analysis. 
Nine patients were female and thirty-six were male. The 
anthropometric data and general characteristics of the patients 
examined are reported in Table 1. 
 
Table 1. General characteristics of the examined COPD patients 
No. 45 
Age, yrs (mean±SD) 69.9±7.1 
Male/Female 36/9 
Smmokers/Ex-smokers 8/37 
Pack-years (mean±SD) 50.8±28.2 
BMI (mean±SD) 26.9±4.5 
Time from diagnosis, yrs (mean±SD) 7.2±6.0 
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FEV1, %pred (mean±SD) 52.5±17.0 
MRC score (mean±SD) 1.7±1.2 
N°exacerbations/2years(mean±SD) 1.9±2.1 
 
Inclusion criteria for the enrollment in the present study were: 
a) COPD, defined according to clinical characteristics and a 
FEV1/SVC ratio ≤ 88/89 % of the predicted value (36); 
b) age > 40 years 
c) current or past smoking habit, with ≥10 pack-years 
d) currently attending to repeated clinical and functional 
assessment in our unit in the last 2 years 
Exclusion criteria were represented by: 
a) an important asthmatic component of COPD, as 
assessed by a clinical history of symptoms beginning before 40 years 
of age, and a very large variability of FEV1 (> 20%) in the spirometric 
measurements obtained in the previous 2 years. 
b) presence of chronic respiratory failure 
c) COPD exacerbation within the previous 4 weeks 
d) diagnosis of cancer in the previous five years 
e) any severe comorbidity condition which did not allow to 
perform the CPET 
 
Study design 
 
The study is a cross-sectional study and took place in three visits, 
along a study period of 2 weeks. 
In the first visit, the investigator explained to the patient the study 
protocol and collected the written informed consent. After the 
assessment of the inclusion and exclusion criteria,  the investigator 
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completed the clinical record form (CRF) and explained how the 
patient should discontinue the current therapy, if performed, before the 
following visits, according to the following schedule: inhaled 
corticosteroids: 2 weeks before; long-acting anticholinergic drugs and 
theophylline: 48 hrs before; LABA: 24 hrs before. The patients wear 
the Armband and received a diary to record the time and level of 
physical activity. 
In the second visit, performed at 1 week interval,  the investigator 
checked for the appropriate withdrawal of the therapy, and then 
performed the following measurements: venous blood sampling, 
bioelectrical impedence (for FFM index), maximal inspiratory and 
expiratory pressure, shuttle walking test, Saint George‟s Respiratory 
Questionnaire, pulmonary function test (including static lung volumes 
and diffusing capacity) with bronchodilator test. All measurements 
were performed after an appropriate period of rest. 
In  the third visit, the investigator checked again for the 
appropriate discontinuation of the regular therapy, then measured 
resting arterial blood gasanalysis and performed the CPET. After 
appropriate resting period, induced sputum was collected The patients 
then were removed from the Armband and reported  the diary. 
 
Methods 
 
Pulmonary functional assessment 
The patients performed pulmonary function test for the evaluation 
of dynamic and static lung volumes, the measurement of the flow 
limitation and of diffusing lung capacity of carbon monoxide, by a 
Medical Graphics Elite Series Tm Plethysmograph. Reference values 
were derived from (36) and the results were interpreted according to 
the ERS criteria.  
Disease severity was classified according to the GOLD staging 
system (37), considering the post-bronchodilator FEV1 
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Flow limitation was measured by the Hyatt method, according to 
Hyatt technique, by overlapping the tidal and maximal flow volume 
loops. We used a dedicated softwear that aligns flow volume course.   
(38) .  Also transfer of carbon monoxide was measured by  Medical 
Graphics Elite Series Tm Plethysmograph. The results was according 
to ERS criteria. (39) 
 
Arterial blood gasanalysis 
Arterial blood analysis was done before of cardiopulmonary 
exercise test and was analyzed by BGE 1400. 
 
Respiratory muscle strength 
Maximal inspiratory (MIP) and expiratory (MEP) pressures were 
measured by a Morgan equipment. Three acceptable manouvres of 
maximal inspiratory and expiratory manouvres against closed airways 
were measured at residual volume or total lung capacity, respectively. 
Lung volume at the beginning of the forced manouvres were checked 
by the connection to a computerized water-sealed bell spirometer 
(Biomedin, Padova, Italy).  
 
Incremental shuttle walking test (ISWT) 
It was performed according to the standard recommendations 
(40).  Shortly, patients were asked to walk around an elliptical course 
at a progressively increasing speed dictated by the cassette recording. 
Patients were instructed, monitored and incentivated during the test 
according to the standard recommendations. The test was interrupted 
if the patient: a) were too breathless to continue with the test; b) failed 
to reach the cone in the allowed time, i.e. defined as being > 0,5 m 
away from the cone; c) exceeded 85% of their predicted maximal heart 
rate. Two repetitions of the test were obtained after a short resting 
period, and the highest value of performance was considered. 
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Cardiopulmonary exercise test (CPET) 
CPET was performed on a cycle-ergometer Cardioline, using a 
progressively increasing work load generated by a ramp protocol, and 
metabolic, ventilatory and cardiac measurements were obtained by a 
software ZAN Ferraris CardioRespiratory. The procedures for 
performing, monitoring and assessing the results of the test were 
derived from the ATS/American College of Chest Physician document 
(15). All exercise parameters were calculated using formulas 
described by Wasserman et al.(16). 
The protocol included the following three steps: resting (3-min 
duration, with the patient sitting up, not pedaling); warming-up (3-min 
duration pedaling against no resistance); and symptom-limited 
exercise, by encouraging patients to reach exhaustion. Throughout the 
exercise test patients were encouraged to maintain a pedaling 
frequency about 50 to 60 rpm. Work was increased at a rate of 10 
W/min. During the test, flow rate at the mouth and gas exchange 
variables were recorded breath by-breath, cardiac frequency  and 
percentage oxygen saturation (SpO2%) were determined using the R-
R interval from a 12-lead on line electrocardiogram and a pulse-
oxymeter, respectively. 
Exercise performance was expressed as maximum specific VO2 
(VO2peak/Kg), in L/min/kg) during a workload sustained for 1-min at 
least. 
Inspiratory Capacity (IC) was measured each minute during the 
test and the IC/TLC was calculated using the plethysmographic TLC 
value (41). 
  
Physical activity 
Physical activity was measured over at least 7 consecutive days, 
using a multisensory armband (SenseWear Armband, BodyMedia Inc., 
Pittsburgh, PA) which was worn on the upper right arm over the triceps 
muscle. It incorporates a biaxial accelerometer that records steps per 
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day, and physiologic indicator of energy expenditure that enables the 
investigator to determine the physical activity level. Patients used also 
a diary card for reporting the awaking and sleeping time, and the 
duration and type of exercise. 
 The following measurements were derived, as a mean value of 
the entire period of monitorig: total number of steps/day, total energy 
expenditure (TEE, in Kcal), active energy expenditure  (AEE , as Kcal), 
time of physical activity  (TPA, minutes).(42) 
 
Metabolic status  
Body mass index (BMI: weight (in Kg/height (in m)2), Fat Free 
Mass (FFM, in Kg/height (in m)2) and Fat Free Mass Index (FFMI), 
were measured by bioelectrical impedence analisys Bodygram-Pro 
3.0, Akern. BMI < 20 selected the underweighted patients, BMI 21-25 
individuated normal weight patients, while BMI 26-30 and > 31 was 
used to individuate overweight and obese patients, respectively. A 
value of FMMI > 15 Kg /m2in the women and < 16 Kg/m2  was 
considered as indicative of malnutrition. (43) 
 
Health-Related Quality of Life 
The Saint George‟s Respiratory Questionnaire (SGRQ) was used 
for the assessment of the health-related quality of life. Total score and 
specific sections scores were expressed in % of maximum available 
score (44) 
 
Comorbidity 
Charlson index and CIRS index (Cumulative illness rating scale ) 
were used as valid and reliable methods to measure comorbidity (45). 
The percentage of patients with at least one comorbid condition and 
the mean number of comorbidities were considered in the analysis. 
 
Marker of airway and systemic inflammation 
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In a sample of venous peripheral blood, the following biomarkers 
were measured: C-reactive protein (CRP), total and differential 
inflammatory cells, haemoglobin and N-terminal pro–B-type natriuretic 
peptide (NT-pro-BNP) concentration, as a systemic biomarker of heart 
failure. (46). Measurements were performed in the local Central 
Laboratory using standards methods. (NT–pro- BNP) was used  
Anemia was defined by WTO criteria (47), as haemoglobin level 
below of 13 gr/dl in men and 12 gr/dl in women. On the serum, tumor 
necrosis factor alfa (TNF-alfa) and interleukin-8 (IL-8) were measured, 
using standard immunoenzymatic tests (ELISA); reference values 
were derived from Higashimoto et al and Schols et al. (48-49) 
Sputum was induced according to the method previously 
described (50), using salbutamol pretreatment, hypertonic saline 
(NaCl, 4.5%) nebulized with an ultrasonic nebulizer (Ultraneb 2000, 
DeVilbiss, Somerset, Pa., USA) for 5-minute periods for up to 15 
minutes, and FEV1 measurement before and every 5 minutes. 
Inhalation was stopped in presence of symptoms of  
bronchoconstriction, or excessive FEV1 decline. The whole sputum 
sample was diluted with an equal volume of 0.1% dithiotreithol 
(Sputasol; Unipath Ltd, Basingstoke, UK). Samples were treated as 
previously reported (51). Macrophage, lymphocyte, neutrophil, 
eosinophil percentages were expressed as percent of total 
inflammatory cells, excluding squamous cells. In the sputum 
supernatant, TNF-alfa,  IL-8 and neutrophilic elastase (NE) were 
measured (52) 
Exhaled nitric oxide (NO) was measured in real time by a NOA 
Sievers analyzer (GE Analytical Instruments), on a single breath of 10 
seconds against a resistance that resulted in an expiratory flow of 50 
ml/sec. Normal value was posed at 25 ppb, according to previous data 
on general population (53) 
Exhaled breath condensate (EBC) was collected by a Ecoscreen, 
(Jaeger, Wurzburg, Germany) during a steady-state resting breathing. 
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Malondhyaldehyde (MDA) as a marker of oxidative stress, was 
measured according to a method previously described (54)  
 
STATISTICAL ANALYSIS 
 
Statistical analysis was performed on the data obtained in the 45 
patients who performed all measurements. All statistical analyses 
were performed using a SPSS 16.0 statistical package. The values of 
the different variables were expressed as mean ± standard deviation, 
or as median and range for variable non-normally distributed (most 
biomarkers). To assess the normality distribution of all variability, 
Shapiro-Wilk test was used. Correlations among the different variables 
were performed using Pearson correlation or Spearman correlation for 
normally and non-normally distributed data, respectively. A p value < 
0-05 was considered as significant. 
In order to evaluate the minimum number of patients to be 
studied, a preliminary power analysis was performed, according to 
previous papers with the aim to study the main determinants of the 
exercise capacity in COPD patients. Considering FEV1/VC ratio as a 
major determinant of the exercise capacity obtained by the CPET, a 
number of 29 patients might have a 80% power (with a p < 0.05) for 
detecting a significant influence by spirometric indices (and possibly by 
other variables) on the exercise capacity. 
 Because several clinical, functional and biological 
characteristics resulted significantly correlated with the dependent 
variable used as marker of exercise capacity (specific VO2peak) in the 
univariate analysis, we selected for each group of variables (clinical, 
functional, nutritional, and biological) only these independent variables 
which were significantly correlated with specificVO2peak in the 
univariate analysis and which did not have consistent interaction 
among them, due to the fact that they might express the same clinical, 
physiological or biological aspect of the disease. With these selected 
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variables, a multivariate step-wise regression analysis was performed, 
using specificVO2peak as independent variable, and all the other 
variables as dependent variables expressed as continuous or 
categorical variables (manual SPSS step-wise). In the last situation, 
categories were binary (0=absence, 1= presence of the condition).  A 
p-value < 0.05 was considered as significant. In this analysis, the R2 
single and cumulative values for all variables significantly correlated 
with specific VO2peak were considered. 
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CHAPTER IV 
 
 
RESULTS 
 
Characteristics of the whole group of COPD patients 
 
 The percent distribution on the 45 patients included in this study 
is shown in Figure 4. More than 50% of patients were included in the 
GOLD Stage 2. 
 
Figure 3. Percent distribution of patients according to GOLD 
stages. 
GOLD 1
GOLD 2
GOLD 3
GOLD 4
 
 
Analyzing the functional respiratory parameters, the patients 
showed on average a degree of airway obstruction of moderate-
severe level,  an increase of TGV %, RV % and RV/TLC %, while TLC 
% was in normal limit. The IC % was slightly reduced, as well as 
DLCO % of predicted  (Table 2).  
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Table 2. Mean values (and SD) of the functional parameters in 
the whole group 
 Absolute value % predicted 
FEV1/FVC, % (mean+SD) 47.1±12.5 63.2±16.4 
FEV1, L (mean+SD) 2.89±1.40 52.6±17.0 
FVC, L  (mean+SD) 2.91±0.81 86.8±18.5 
SVC, L (mean+SD) 3.03±0.84 90.5±18.5 
FEV1/SVC,  % (mean+SD) 44.9±11.3 57.9±14.6 
IC, L (mean+SD) 2.17±0.75 77.5±20.5 
TGV, L (mean+SD) 4.82±1.12 142.7±28.3 
RV, L (mean+SD) 3.89±0.96 161.4±35.6 
TLC, L (mean+SD) 6.93±1.27 113.4±14.8 
RV/TLC % (mean+SD) 54.9±11.0 135.9±21.4 
DLCO, ml/min/mmHg 
(mean±SD) 
17.1±6.8 70.9±26.1 
 
Flow limitation was measured in 44 out of 45 patients. According 
to the definition of low limitation measured with the Hyatt method.(38) , 
35 out of 44 (79.5%) resulted flow-limited. 
Resting arterial blood analysis showed the presence of a mild-to-
moderate hypoxemia (PaO2: 77.5±8.9 mmHg) while PaCO2 and pH 
were still in the normal range (paCO2: 39.4±4.3 mmHg; pH: 7.40±0.1). 
No patient was in chronic respiratory failure requiring long-term 
oxygen therapy or domiciliary noninvasive pulmonary ventilation. 
 Respiratory muscle strength resulted in the normal range. 
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 These data seem represent a representative sample of patients 
with moderate-severe degree, according to the current COPD 
Guidelines (1).  
In the table 3 reduced, with a low exercise breathing reserve. 
Maximal heart rate was largely lower than the maximal predicted 
value, the heart rate reserve was high and the pulse in oxygen was 
normal, suggesting that these patients had a minimal limitation in the 
exercise due to heart cause are reported the results of the CPET and 
of the ISWT. The patients showed a mild-moderate reduction of 
exercise tolerance,  considering the VO2peak and the work load max. 
However, maximal ventilation reached at the of the exercise was 
moderately. Only 16 patients reached the anaerobic threshold, while 
all remaining subjects or not reached or was indeterminate. Vd/Vt was 
on average high both at baseline (35.58±5.4 %) and at the peak of 
exercise (33.29±6.6), suggesting of mismatch ventilation -perfusion). 
Arterial blood pressure increased from the baseline (127±21/80±12 
mmHg) to the end of exercise (180±29/86±16 mmHg), showing a 
normal adaptation of the cardiovascular system to the exercise. Borg 
dyspnoea score increased significantly from baseline to the end of 
exercise (0.3+0.5 vs 5.3+2.2), as well as Borg muscle fatigue score 
(02+0.7 vs 3.9+3.1) although in a minor degree.  
 
Table 3. Mean values (and SD) of the main results obtained 
during the CPET and the ISWT in the whole group of COPD patients 
 Absolute value % predicted 
Cardiopulmonary exercise test   
VO2peak, L/min (mean+SD) 1.33±0.5 76.3±20.4 
VO2peak/Kg, ml/min/Kg (mean+SD) 17.5±5.5 75.4±21.8 
Work Load max, watts (mean+SD) 74.0±32.1 55.0±19.5 
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Heart Rate max, bpm (mean+SD) 114±14  
Heart Rate Reserve ,bpm (mean+SD) 46±18 77.5±20.5 
O2 pulse max, ml/beat (mean+SD) 15.4±4.8       108.9±31.3 
ΔVO2/ΔWatt,ml/min/watt (mean+SD) 10.2±3.0  
Anaerobic thr., L/min (mean+SD) 1.42±0.41 72.6±21.7 
VE max, L/min (mean+SD) 38.0±13.5 48.5±14.7 
EBT, L/min (mean+SD) 9.07±11.6  
Shuttle walking test    
Distance, m (mean+SD) 284.4±128.0  
 
Patients travels 284 meters during the shuttle walking test.  Borg 
dyspnoea score  was  low al rest (0.4+0.8) but became significant at 
the end of the test (4.7+2.3). The same trend was observed for Borg 
muscle fatigue score (from 0.4±1.2 to 2.1±2.6). 
Oxygen saturation was normal at the beginning of the CPET, at 
the end was less than 3 point (from 95.2± 1.5 to 92.3±3.4) 
Therefore, the results of the two exercise tests confirmed that the 
major locus for the limitation of the exercise was the ventilatory 
limitation, with mild support from cardiac and peripheral muscular 
limitations.   
In Table 4 are reported the parameters of the body composition. 
The majority of these COPD patients were overweight,  and also FFM 
in % pred. was mildly reduced. However, FFMI was in the normal 
range, suggesting that the reduction in FFM was poorly relevant in 
these patients.   
 
Table 4. Mean values (and SD) of the nutritional data measured 
in the whole group of COPD patients 
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BMI, Kg/m2 (mean+SD) 27.0±4.5 
FFM, Kg (mean+SD) 51.0±10.2 
FFM, % pred (mean+SD) 67.6±7.2 
FFM Index, Kg/height2 (mean+SD) 17.9±2.7 
 
Quality of life measured with Saint George‟s Respiratory 
Questionnaire (Table 5) showed a major limitation in the activity 
section, due to the fact the patients had minor capacity to perform the 
normal activity of daily life (walking, leaving the house) and spent most 
of time in lying, sitting or standing, probably in order to tolerate the 
dyspnoea. Dyspnoea according to the Medical Research Council 
(MRC) scale was 1.7±1.2. 
 
Table 5. Mean values (and SD) of the total score and of the 
scores obtained in the different sections of the St. George Respiratory 
Questionnaire, in the whole group of COPD patients 
Symptoms, % (mean+SD) 39.7±19.6 
Activity, % (mean+SD) 53.6±24.3 
Impact, % (mean+SD) 29.8±16.9 
Total, % (mean+SD) 38.5±16.8 
 
As regards comorbidities, the Chalson Index was 2.04+1.1, while 
the CIRS index was 2.77+1.1 and the CIRS severity index was 
1.56+0.2, suggesting that few comorbidities were present. 
The parameters of daily physical activity measured with Armband 
are reported in Table 6. The patients reported a low physical activity 
measured with steps/day according to the classification of physical 
activity proposed by Tudor-Locke. (55.). According to this classification 
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of physical activity using different cut-points for healthy adults, our 
COPD patients were included as a mean in the low active group 
(5,000 to 7,499 steps/day), with some patients were included in the 
category of inactive subjects (< 5,000 steps/day). Considering that in 
2009 the original sedentary level was further spliced into two 
additional levels: <2,500 steps/day (basal activity) and 2,500 to 4,999 
steps/day (limited activity) (56), these patients were almost all included 
in the category with limited activity.   
 
Table 6. Mean value (and SD) of the indices derived from the 
monitoring of the physical activity by the Armband, in the whole group 
of COPD patients. 
Total Energy Expenditure, Kcal (mean+SD) 2290.1±465.2 
Steps/day (mean+SD) 6411±4152 
Active energy expenditure, Kcal (mean+SD) 356.7±349.3 
Time of physical activity (min) (mean+SD) 75.5±78.1 
METS (mean+SD) 1.29±0.3 
 
The results of the biomarkers measured in the peripheral blood, 
induced sputum and exhaled NO are reported in Table 7 Blood cells 
counts and hemoglobin were in normal range, while inflammatory 
biomarkers (ESR and CRP) were higher than normal, suggesting a 
systemic involvement related to COPD. N-pro-BNP was higher in 50 % 
of patients.  Mean serum TNF-alfa and  IL-8 were in the normal range. 
While microparticles resulted high value (normal value  <2.5 nM) in 
93% of patients. 
 
Table 7. Mean values (and SD) or median values (and range) of 
the biomarkers measured in peripheral blood, sputum and exhaled air, 
in the whole group of COPD patients. 
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Peripheral blood  
Blood Red Cells, cells/ μl (mean+SD) 4976.4±522.2 
Haemoglobin, gr/dl (mean+SD) 14.6±1.3 
Neutrophils,  cells/ μl (mean+SD) 4,619±1,765 
Neutrophils, %  (mean+SD) 63.1±8.9 
Eosinophils, cells/ μl (mean+SD) 276.2±274.8 
Eosinophils, %  (mean+SD) 3.80±3.1 
ESR, 1st hour 28.5 (8-83) 
CRP, (mg/L) 5.6 (1.4-36.4) 
Pro-BNP, (pg/ml) 130.0 (0-1335) 
 TNF-alfa, (pg/ml) 58.6 (20-242,7) 
IL-8, (ng/ml)  10.1 (0.2-24.8) 
Microparticles, (nM) 7.9 (1.6-34.3) 
Induced sputum  
Neutrophils, % (median, range) 73.8 (37.0-97.1) 
 Eosinophils  % (median, range) 3.1 (0.0-59.6) 
TNF-alfa, (pg/ml) (median, range)     122.7 (9.1-904.5) 
 IL-8, (ng/ml) (median, range) 13.4 (0.2-50.7) 
Neutrophil Elastase, μg/ml (median, range) 2.84 (0.1-8.0) 
Exhaled breath  
 FeNo, ppb (median, range) 18.9 (4.2-90.4) 
MDA in EBC,  nM (median, range) 25.2 (3.7-101.3) 
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Sputum induction confirmed the predominant neutrophilic airway 
inflammation of these COPD patients. However, although average 
sputum eosinophil percentage was only slightly increased (upper limit 
of sputum eosinophil percentage may be considered as 2%, (57). 17 
out of 43 patients showed a sputum eosinophil percentage > 3%, with 
some subjects showing very high levels of sputum eosinophilia. A 
revision of the clinical history of these patients and their FEV1 
variability over time demonstrated no findings suggestive of asthma 
component (except for one patient who was discarded from the 
analysis. 
Soluble mediators measured in the supernatant of the induced 
sputum confirmed the characteristics of a neutrophilic airway 
inflammation. 
 Exhaled nitric oxide (FeNO) was as a mean in the normal 
range; however, 12 out of 35 patients had a FeNO higher that 25 ppb 
(upper normal limit). 
Malondhyaldeyde in the exhaled breath condensate was as 
average higher than normal subject, and in particular 23 out of 36 
patients had an abnormal MDA value.(54) 
Flow limited patients were 36 out of 45, confirming the moderate-
severe grade of obstruction.  
 
Correlations among variables 
 
 Because the main objective of our study was to determine the 
relative role of several clinical, functional and biological findings on 
exercise tolerance measured at CPET in this group of moderate-
severe COPD patients, we considered as dependent variable 
VO2peak/kg, which may be considered the best way for expressing 
exercise limitation during CPET, and as independent variable all these 
findings which may potentially have some influence in determining the 
amount of the exercise limitation. 
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Simple regression analysis for VO2peak/kg   
In an univariate single regression analysis, V02peak/Kg was 
significantly correlated with several clinical and functional parameters, 
but not with the majority of nutritional and biological markers (Tables 
8).  
 
Dependent Variable Independent Variable P R 
 
 
 
 
 
 
 
 
 
 
 
VO2peak/Kg 
Age  N.S.  
Male/Female N.S.  
Pack-years  N.S.  
N°. exacerbations N.S.  
N°. comorbidities N.S.  
MRC score 0.0001 -0.556 
FEV1/FVC %   N.S.  
FEV1, % pred. 0.007 0.396 
FVC,  % pred. 0.033 0.318 
SVC, % pred.  0.046 0.299 
FEV1/SVC, % 0.055 0.288 
IC, % pred.  0.0001 0.506 
TGV, % pred.  N.S.  
RV, % pred.  N.S.  
TLC, % pred.  N.S.  
RV/TLC, % pred.  0.003 -0.437 
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DLCO, % pred. 0.0001 0.517 
 
 As shown in Table 8, VO2peak/kg was significantly correlated 
with FEV1, IC and RV/TLC%, while the correlations were poor with the 
major indices used for the definition of airway obstruction (FEV1/FVC 
and FEV1/SVC). Because FEV1% may be also influenced by the level 
of hyperinflation, the observation suggest that probably hyperinflation 
may influence more than airway obstruction the exercise performance 
in these patients. Diffusing capacity showed the highest level of 
correlation with VO2peak/kg, explaining by itself a consistent part of 
the variance (r2: 0.267). 
 Arterial blood gas analysis parameters did not show any 
significant correlation with exercise capacity, as expressed by 
VO2peak/kg. This fact is not unexpected, considering that no patients 
had chronic respiratory failure and that the range of resting hypoxemia 
was fairly limited. Maximal inspiratory and expiratory pressure, as 
expression of the strength of the inspiratory and expiratory muscles, 
were in normal range (MIP: 56.2 ± 22.1, MEP: 89.9 ± 49.3) and did not 
correlate.   
 Nutritional data (BMI, FFM and FFMI) were not correlated with 
VO2peak/kg, with a r value ranging from 0.022 to 205 (all n.s.). 
 As regards the correlation with biomarkers measured in the 
blood, sputum and exhaled condensate (Table 9), we can see that 
there was no significant correlations of VO2peak/kg for many 
biomarkers, except for some indices of systemic inflammation (blood 
neutrophil percentage, serum IL-8 and blood microparticles) which 
were negatively associated with exercise performance, and for blood 
haemoglobin which was positively associated with exercise 
performance. No correlation was observed for biomarkers measured in 
the sputum or in exhaled air. 
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Table 9. Univariate analysis, using as dependent variable 
VO2peak/kg and as independent variables all biomarkers measured. 
Dependent Variable Independent Variable P R 
 
 
 
VO2peak/Kg 
Blood Neutrophils, % 0.013 - 0.367 
Blood IL-8 blood 0.004 - 0.497 
Serum N-Pro-BNP  0.0001 - 0.564 
Blood haemoglobin 0.018 0.351 
Microparticles  0.051 - 0.304 
 
Multivariate regression analysis for VO2peak/kg 
 In order to verify which might be, among the various variables 
significantly correlated with VO2peak/kg, those which may have the 
more relevant role in determining the level of exercise tolerance, we 
performed a multivariate step-wise regression analysis. At this 
purpose, we considered VO2peak/kg the only dependent variable, and 
all clinical, functional and biological variables which were resulted 
significantly correlated with VO2peak/kg in the univariate analysis 
(table 10) 
 
Table 10-a. Results of the multivariate step-wise regression 
analysis using different models  
Model 1 
Independent variable P R R2 
Blood haemoglobin 0.024 0.562 0.315 
MRC score N.S.   
FEV1% N.S.   
IC % N.S.   
DLCO % N.S.   
Blood Neutrophils, % N.S.   
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Blood IL-8 blood N.S.   
Serum N-Pro-BNP  N.S.   
Microparticles N.S.   
SGRQ tot % N.S.   
 
Table 10-b. Results of the multivariate step-wise regression 
analysis using different models  
Model 2 
Independent variable  P R R2 
MRC scale 0.03 0.453 0.205 
FEV1% N.S.   
IC % N.S.   
DLCO % N.S.   
Blood Neutrophils, % N.S.   
Blood IL-8 blood N.S.   
Serum N-Pro-BNP  N.S.   
Microparticles N.S.   
SGRQ tot % N.S.   
 
 
We accurately selected all single variables which were 
significantly correlated with VO2peak/kg, in order to avoid to include in 
the multivariate analysis variables which may be strictly correlated 
between them or which may express the same pathophyisiological 
mechanisms (e.g.. IC and RV/TLC, etc). We combined different 
models for performing multivariate step-wise analysis, and we 
observed that in model 1 the only variable that explains the model was 
blood haemoglobin. Total variance explained by this model was 31.5% 
In Model 2,excluding haemoglobin aspecific parameters,  the 
variable that explains the model is MRC score, with total variance 
explain of 20.5 %. 
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In model 3 we consider one independent variable for each clinical 
, functional and biological field. DLCO % is the variable that explains 
the model and total the variance explain was 19.6%. 
 
Table 10-c. Results of the multivariate step-wise regression 
analysis using different models  
Model 3 
Independent variable  P R R2 
DLCO % 0.016 0.443 0.196 
FEV1% N.S.   
IC % N.S.   
MRC score N.S.   
Blood haemoglobin N.S.   
Serum N-Pro-BNP N.S.   
Blood Neutrophils, % N.S   
 
Other correlations for VO2peak/kg 
 Because other findings we collected in this group of COPD 
patients may be correlated with exercise capacity measured during 
CPET, because they are expression of or are strongly influenced the 
same exercise limitations, we performed also other correlations, 
always including VO2peak/kg as dependent variable. 
 The response to the ISWT, in terms of meters performed during 
the test, was significantly related, as expected, to VO2peak/kg (r = 
0.667, p< 0.0001). This partial correlation may be explained by the 
different characteristics of the two tests. 
 Physical activity was monitored in our patients using a 
Multisensor Armband.  
Among the different indices obtained, only the number of steps 
per day and the total energy expenditure were significantly correlated 
with the VO2peak/kg, suggesting that not the duration of periods with 
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high-intensity exercise but rather the level of the global physical 
activity may be related to this instantaneous measure of exercise 
capacity obtained in laboratory. 
 
Table 11 Univariate analysis, using as dependent variable 
VO2peak/kg and as independent variables the indices derived from 
the monitoring physical activity by Multisensor Armband 
Dependent variable Independent variable  P R 
 
 
VO2peak/Kg 
Total Energy Expenditure (Kcal) 0.005 0.428 
Steps/day 0.0001 0.499 
Active energy expenditure (Kcal) N.S.  
Time of physical activity (min) N.S.  
METS N.S.  
 
Finally, St. George Respiratory Questionnaire, both as total score 
and as single sections score, resulted significantly correlated with 
VO2peak/kg (Table 12). This fact may be easily explained in terms 
that exercise limitation (as expressed by VO2peak/kg) represents a 
major factor in determining the quality of life of these patients. As 
expected, the “activity” section showed the highest level of correlation 
with VO2max/kg. 
 
Table 12. Univariate analysis, using as dependent variable 
VO2max/kg and as independent variables data derived from St. 
George Respiratory Questionnaire. 
Dependent variable Independent variable  P R 
 
VO2peak/Kg 
Symptoms, %  0.026 - 0.336 
Activity, %  0.0001 - 0.590 
Impact, %  0.022 - 0.332 
Total, %  0.0001 -0.556 
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Correlations in selected subgroups 
 We evaluated patients flow limited (FL) and not flow limited 
(NFL). 
Only in the FL group the VO2peak/Kg correlated in univariate analysis 
with a several clinical functional and biological indices Table 13. In 
stepwise regression analysis MRC and IC% were the parameters that 
enter in the analysis, with cumulative R2= 0.454.  
 
Table 13. Univariate analysis, using as dependent variable 
VO2peak/kg and as independent variables all clinical, biological and 
functional variables available 
Dependent variable Independent variable  P R 
 
 
 
VO2peak/Kg 
MRC scale 0.001 - 0.623 
FEV1% 0.0001 0.393 
IC % 0.002  0.563 
DLCO % 0.0001 0.562 
ICcpet/TLCph 0.0001 0.392 
Blood haemoglobin 0.03 0.390 
Serum N-Pro-BNP 0.02 -0.583 
Steps/day 0.02 0.489 
SGRQ tot % 0.004 -0.569 
 
The baseline difference in functional parameters between 2 groups 
were DLCO % (FL: 68.1±22.9, NFL: 87.8±32.8). The FL had FEV1 % 
(51.1±17.2) lower than NFL (62.4±12.4), but this difference was not 
statistically significant. 
Considering the patients that had interrupted the CPET for ventilator 
limitation (30 patients out of 45),  the table 14 shows the univariate 
correlation. 
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Table 14. Univariate analysis, using as dependent variable 
VO2peak/kg and as independent variables all clinical, biological and 
functional variables available 
Dependent variable Independent variable  P R 
 
 
 
 
 
VO2peak/Kg 
MRC scale 0.0001 - 0.622 
FEV1% 0.038 0.380 
IC % 0.004  0.504 
RV/TLC % 0.011 - 0.455 
DLCO % 0.001 0.584 
MIP % 0.013 0.516 
Serum N-Pro-BNP 0.043 -0.666 
Steps/day 0.002 0.561 
TEE 0.014 0.451 
ISWT 0.0001 0.778 
SGRQ tot % 0.004 -0.569 
 
In stepwise regression analysis were excluded ISWT and parameters 
of Armband; only MRC entered in the model (p= 0.021, R= 0.589) and 
explained the  34.7% of variance of exercise tolerance.  
In the patients that interrupted the CPET for muscular limitation (15 
patients), the exercise tolerance not correlated with functional 
parameters but several indices: age, blood neutrophils %, blood 
eosinophils %, sputum neutrophils %, ISWT (respectly R= - 0.547, -
0.513, 0.573, -0.675, 0.583). This patients had less compromise in 
FEV1% (44.9±13.2 vs 67.9±13.0) and higher MRC score (2.0±1.2 vs 
1.±1.1) than the 30 patients that stopped CPET for ventilator limitation. 
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CHAPTER V 
 
DISCUSSION 
 
In the present cross sectional study, we tried to examine the 
determinants of the exercise limitation which is a characteristic of the 
patients with moderate-severe COPD. We included a large, although 
not exhaustive, series of clinical, functional and biological 
measurements, in order to find which variable, among those 
considered, might have the predominant role in determining the 
limitation in exercise capacity. We chose the maximum specific 
oxygen consumption (VO2peak/kg), obtained during a CPET, as a 
good marker of the exercise limitation in our COPD patients. We found 
that several clinical, functional and biological variables were 
significantly correlated with VO2peak/kg. Many of these correlations 
were expected according to the pathophysiology of the disease (like 
MRC, IC, DLCO), but some of them were fairly unexpected (like some 
biomarkers). Furthermore, our study was not able to show significant 
correlations with other variable which may be considered as possible 
determinants of the exercise capacity (like respiratory muscle strength, 
BMI or FFM). When me included the variables which resulted 
significantly correlated with VO2max/kg in a multivariate step-wise 
regression (according to different models), we found that the man 
determinants were haemoglobin and, in a second position, MRC 
dyspnoea score and diffusing capacity. This was particularly true when 
only subjects with pulmonary mechanical factors which may limit 
exercise (like the presence of flow limitation), or with a respiratory 
limitation to the CPET, were considered. This suggest that the main 
factors limiting the peak oxygen consumption during exercise are 
represented by non-pulmonary mechanisms in all unselected COPD 
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patients, and by pulmonary mechanisms in COPD patient with clear 
limitation to the exercise related to the pulmonary disease. 
 
Characteristics of the examined COPD patients.  
We examined COPD patients with a moderate to severe disease, 
with a level of reduction in lung function which usually is accompanied 
by symptoms and limitations in daily life. In addition, there was, on 
average, a moderate lung inflation and a moderate reduction in the 
exchange function lung (as demonstrated by the reduction of the 
spread of lung CO). They have a substantial reduction in quality of life 
related to disease (especially detectable in the limitation of daily 
activities) and, during an effort to incremental load (10 watts per 
minute), report dyspnea, and particularly, to a lesser extent, muscle 
fatigue. From a nutritional point of view do not show weight loss or loss 
of lean body mass. It is well known that a greatly reduced BMI, as well 
as the index of lean body mass, are elements that characterize only a 
minority of subjects with COPD, usually those with very serious and 
strong limitations in daily life (58). Finally, markers of bronchial and 
systemic inflammation showed, in this group of patients, only mild 
abnormalities: only in induced sputum, there was an increased 
neutrophil and eosinophil percentages, according to that already 
observed in other studies (59-60) 
 
Correlations in the univariate analysis 
The primary outcome in this study was to find a correlation 
between exercise tolerance and the  FEV1/SVC ratio, the main index 
of the airway obstruction. We found only a weak significant correlation 
(p= 0.055, R= 0.288). Diaz et al. (29) found a good correlation 
between VO2 % predict and FEV1/FVC ratio but probably because 
their patients were less severe than patients enrolled in this study. 
This correlation is probable due to the fact that a high FEV1/FVC ratio 
reflects a maximal expiratory flow volume curve with an upward 
 57 
convexity, which implies a large flow reserve over the resting tidal 
volume range, while a low FEV1/FVC ratio reflects a curve with an 
upward concavity with little expiratory flow reserve over the resting 
tidal volume range. (61). Other functional parameters, like indices of 
airway obstruction (FEV1 %, FVC %, SVC%) or hyperinflation (IC % 
an ICCPET/TLCph), correlated with VO2/Kg. This is in agreement with 
the data observed by other authors, both in an univariate analysis and 
in multivariate analysis (29). Even CO diffusing capacity appears to 
contribute to the effort limitation in these patients. ICCPET/TLCph had the 
highest degree of correlation (R= 0.516), and therefore the dynamic 
lung hyperinflation was proven to be a major factor explaining the 
difficulty of COPD patients to achieve an adequate level of physical 
activity, such as suggested by various clinical and pathophysiological 
studies (62). 
Among the clinical parameters, exercise tolerance was indirectly 
correlated, as expected, with the degree of dyspnea (MRC score). In 
fact severe dyspnoea is a major exercise-limiting symptom in 
moderate-severe COPD. The dyspnoea follows a linear relationship 
with work rate  and oxygen uptake during incremental exercise in both 
healthy subjects and patients with respiratory disease. (63). The 
mechanisms of dyspnoea are multifactorial , but abnormal dynamic 
ventilator activity is believed to play a central role. 
Kontogiorgi et al. (64)  found a strong correlation between Work 
load and MRC (R= - 0.91), while in the study of Brestall et al. (65) the 
shuttle walking distance was assessed in 100 COPD patients, the 
distance decreasing significantly from grade 3 to higher dyspnea 
levels.  
On the contrary, we found no correlation between exercise 
tolerance and parameters of nutritional status. It should be noted that 
these included both the BMI and indices of lean body mass (FFM, in 
absolute terms and as% of predicted, and the FFMI), and that these in 
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our sample were related to overweighted patients and with low 
physical daily activity. 
The exercise tolerance correlate with blood neutrophils, as a 
marker of systemic inflammation. In fact they represent the 
characteristic pattern of the inflammation observed in the lung, but 
also in the peripheral blood of COPD patients , as a markers of 
systemic inflammation. Patients with stable COPD present increased 
numbers of leukocytes and increased levels of acute phase response 
proteins (C-reactive protein [CRP], fibrinogen and cytokines [IL-6 and 
tumor necrosis factor]). The intensity of this systemic inflammation 
increases during exacerbations of COPD. In this study we not found a 
relation between exercise tolerance and CRP. Garrod et al. (66) 
observed in 41 patients a indirect correlation between CRP and VO2 
or meters traveled during the six minutes walking test (R= 0.46 and 
0.47 respectly), but these patients reported a degree of dyspnea and 
exercise tolerance worse than those observed in our population.  
 An indirect correlation was found with Pro-BNP. This marker is 
expressive of a cardiovascular disease. In this study, hypertension 
was reportred in 53.3 % of population and ischemic heart disease in 
20 %. In literature  similar percentages have been reported. In fact, the 
comorbidities often associated with COPD were hypertension (55%), 
depression (37%), osteoporosis (28%), diabetes mellitus (27%), 
chronic heart failure (27%) and ischemic heart disease (17%).(67) 
Also the correlation with haemoglobin indicates the importance of 
comorbidities. In this study, 11.1 % are affected by anemia. In 
literature the prevalence of anemia in populations with COPD of 
various severity ranges from 7.5 to 21.0% (68-69) 
Instead, no correlation was found between exercise tolerance 
and number of comorbidities, as expressed by the Charlson Index or 
by CIRS.   
 
Correlations in the multivariate step-wise analysis 
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In the stepwise regression analysis the only variable that explain 
exercise capacity is hemoglobin. It explains  31.5 % of variance of the 
exercise tolerance expressed with VO2peak/Kg.  The red blood cells 
contain hemoglobin, the principal oxygen transport molecule, and any 
decrease in hemoglobin levels, resulting in a decreased blood O2 
content, can compromise the supply of O2 to the tissues during the 
exercise. This fact may be expected, due to the heterogeneity of the 
mechanisms which can affect the exercise tolerance in COPD patients 
not only pulmonary limitation but also muscular and cardiovascular 
limitations). When the effect of hemoglobin was removed, or when 
subjects with real pulmonary limitation were considered, the main 
determinants of exercise tolerance were dyspnoea severity and 
diffusing capacity .  Considering that dyspnoea is not only determined 
by alterations in pulmonary mechanics, a great part of the maximal 
exercise capacity during CPET remain unexplained. 
 
Correlations with other markers of exercise limitation 
A correlation was found between VO2peak/Kg and the quality of 
life assessed by Saint George‟ Resporatory Questionnarie. This is an 
expected correlation. Also in the ECLIPSE study the patients with 
lower 6mWT had a worse score of SGRQ; the best correlation was 
with activity section. (70)  
The correlation between VO/Kg and the daily physical activity, 
measured with Armband, confirms the possibility to assess a new 
aspect in COPD patients. The „„gold standard‟‟ to assess total energy 
expenditure under free-living conditions is the doubly labeled water 
method (71). This methodology, however, is limited by cost and by its 
unavailability outside specialized centers. Simple accelerometers are 
inaccurate at estimating total daily energy expenditure from body 
movement counts only. The Armband incorporates several other 
physiologic sensors that, in conjunction with the accelerometer 
recordings, give a more valid estimate of total daily energy 
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expenditure(72). In this study the patients had a mean low physical 
activity but they had not calculate the different levels of activity during 
the day. In fact with this device it is possible to determine the physical 
activity level by dividing total daily energy expenditure by whole-night 
sleeping energy expenditure (73). A physical activity level of 1.70 or 
greater is defined as active, and a physical activity level greater than 
1.78 is strongly associated with a lower risk of mortality in healthy 
older adults. (71). 
In the study of Watz et al., steps per day, minutes of at least 
moderate activity and physical activity level decreased with the clinical 
stages according to GOLD or BODE index. (35), confirming that this 
measure is a good expression of the severity of the disease. 
 
Limitation of the study 
Our study has some limitation. Firstly, we have not directly 
measured the strength of lower limb muscle, which are main 
determinants of the maximum work load sustained during the CPET. 
This is due toi the fact that this measure may be obtained only using 
some complex and expensive instruments. We used as surrogate the 
maximal inspiratory and expiratory pressure, as expression of the 
strength of the respiratory muscle, but this is not necessarily related to 
the strength of other muscular district. Secondly, we have no 
independent measure of the heart function (like ejection fraction or 
other indices derived from echocardiography). We know that exercise 
limitation is strongly related to the performance of the cardiovascular 
system. However, both considering the level of pro-BNP and also the 
high cardiac reserve observed in our patients during CPET, we believe 
that a cardiac limitation was not present in the large majority of our 
patients. 
 
Conclusions 
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In summary, we demonstrated that many different clinical, 
functional, metabolic and inflammatory factors have influence on the 
maximal exercise capacity obtained in COPD patients during a CPET.  
Among all these variables, hemoglobin represented the main 
determinant of the exercise performance, at least when all COPD 
patients, with different reasons for the limitation of exercise capacity, 
were included. However, when only subjects with pulmonary limitation 
to the exercise (like patients with airflow limitation or patients with 
reduced breathing reserve during CPET) were considered, dyspnoea 
and DLCO % explained a great part of the variance of the specific 
VO2peak obtained during CPET. This may increase the definition of 
the main factors limiting the exercise capacity in COPD patients and 
may suggest possible therapeutical interventions. 
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